NEW YORK (GenomeWeb News) – Waters today reported a 3 percent decline in its third quarter revenues year over year, but the firm said that it sees a stabilization in its end markets after a difficult first half of the year.

The Milford, Mass.-based firm reported total revenues of $374 million for the three-month period ended Oct. 3, down from $386.3 million for Q3 2008. The firm said that 1 percent of that decline was due to adverse foreign currency translation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.